Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$154.80
neg -1.32
-0.85%
Today's Range: 153.53 - 156.12 | AMGN Avg Daily Volume: 4,192,700
Last Update: 01/17/17 - 4:14 PM EST
Volume: 3,402,673
YTD Performance: 6.78%
Open: $155.14
Previous Close: $156.12
52 Week Range: $130.09 - $181.81
Oustanding Shares: 743,922,473
Market Cap: 116,141,176,485
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 4 4 4
Moderate Buy 1 1 1 1
Hold 10 11 11 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.28 2.41 2.41 2.37
Latest Dividend: 1.15
Latest Dividend Yield: 2.95%
Dividend Ex-Date: 02/13/17
Price Earnings Ratio: 13.80
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
13.80 15.60 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-4.97% 7.33% 34.12%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.00 0.20 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.60 0.18
Earnings for AMGN:
EBITDA 10.63B
Revenue 21.66B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $2.78 $2.95 $11.54 $12.25
Number of Analysts 11 7 13 13
High Estimate $2.89 $3.30 $11.65 $12.88
Low Estimate $2.63 $2.77 $11.39 $11.57
Prior Year $2.61 $2.90 $10.38 $11.54
Growth Rate (Year over Year) 6.55% 1.87% 11.16% 6.13%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Ed Ponsi

 | Jan 12, 2017 | 10:00 AM EST
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
RMPIA
By

Guy Ortmann

 | Jan 9, 2017 | 1:33 PM EST
These companies show signs of a change of direction.
RMPIA
By

Jim Cramer

 | Jan 6, 2017 | 11:09 AM EST
After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.
RMPIA
By

Bret Jensen

 | Jan 6, 2017 | 8:22 AM EST
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages.
RMPIA
By

Bruce Kamich

 | Jan 6, 2017 | 8:13 AM EST
Traders could buy a dip to $150 if available or they can buy strength above $155, which ever comes first.
RMPIA
By

Doug Kass

 | Dec 27, 2016 | 10:00 AM EST
Six reasons why the Nasdaq 100 ETF seems ready to pull back.
RMPIA
By

Doug Kass

 | Dec 27, 2016 | 7:00 AM EST
Microsoft (MSFT) , which makes up about 8.6% of the index. Amazon (AMZN) , which has about a 6.4% weighting. Cisco (CSCO) , which accounts for about 2.7% on QQQ. I've previously written that I'm bearish on Cisco on an intermediate-term basis. Non-Tech QQQ Stocks Look Iffy, Too Some non-tech QQQ components could weigh down the ETF in 2017 as well. These include biotech and health care companies such as Amgen (AMGN) , Biogen (BIIB) , Celgene (CELG) , Express Scripts (ESRX) and others, which all could suffer if Trump tries to limit drug-price increases. Comcast (CMCSA) also represents a relatively large QQQ weighting (about 3%), but the cable giant could suffer from continued "cord cutting" by consumers. Tax Cuts Won't Help QQQ Stocks Trump's plan to lower the effective U.S. corporate tax rate won't materially benefit QQQ components. After all, large tech and health care firms in the Nasdaq 100 already g
RMPIA
By

David Katz

 | Dec 23, 2016 | 8:00 AM EST
It's got several newly launched promising drugs, a number of late-stage prospects and strong financials.
RMPIA
By

Bret Jensen

 | Dec 16, 2016 | 8:58 AM EST
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this segment of the market in 2016 and I still believe there is value here.
RMPIA
By

Bruce Kamich

 | Dec 12, 2016 | 9:40 AM EST
The biotech probably needs a period of sideways price action before a new rally to the upper end of the trading range gets underway.
Shares of PG area trading at new January highs this afternoon.  The stock is up over ...
Market slightly down across the board to start the holiday shortened trading week.  N...
This morning, Morgan Stanley reported solid results for Q4, ahead of estimates for both re...
See my Jan. 12, 2017 Real Money Pro article for details on my thought process regarding Ch...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.